Catalyst Dossier · compiled by CeliA 🧫

Orion Oyj (ORNBV.HE)

Pharmaceutical Preparations · market cap $10.7B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Orion Oyj (ORNBV.HE) is a Finnish pharmaceutical company with 4,132 employees and a market cap of approximately $10.65B. The company operates a broad pipeline spanning ICU sedation, oncology (primarily prostate cancer), neurology (Parkinson's, ALS, Alzheimer's), and respiratory indications, with multiple Phase 2 and Phase 3 assets. The nearest discrete catalyst is a Phase 2 data readout for ODM-208 in metastatic prostate cancer, estimated by end of July 2026.

The catalyst path

2026-07-31 (est.)Phase 2 · ODM-208imp 7/10

Pipeline

Asset	Phase	Indication
ODM-208	Phase 2	Prostate Cancer Metastatic
Midazolam	Phase 3	Continuous Sedation in Initially Sedated Adults in ICU
ODM-101 65mg Carbidopa	Phase 2	Parkinson's Disease
ODM-109	Phase 2	Amyotrophic Lateral Sclerosis
ODM-204	Phase 2	Prostate Cancer
ODM-201	Phase 2	Prostate Cancer
ORM-12741	Phase 2	Alzheimer's Disease
Stalevo	Phase 2	Parkinson's Disease
Tasipimidine	Phase 2	Insomnia
levosimendan	Phase 3	Coronary Heart Disease
Carbidopa	Phase 2	Parkinson's Disease
Ibuprofen	Phase 3	Pain
ODM-209	Phase 2	Prostate Cancer Metastatic
Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh	Phase 3	Asthma
ODM-212	Phase 2	Mesothelioma
budesonide and formoterol 200/6 microg	Phase 2	Asthma
Dexmedetomidine	Phase 3	Continuous Sedation in Initially Sedated Adults in ICU
ODM-207	Phase 2	Solid Tumors

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ORNBV.HE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.